- Home
- DMO vs CRDL Comparison
DMO vs CRDL Comparison
Compare DMO & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- CRDL
- Stock Information
- Founded
- DMO 2009
- CRDL 2017
- Country
- DMO United States
- CRDL Canada
- Employees
- DMO N/A
- CRDL N/A
- Industry
- DMO Trusts Except Educational Religious and Charitable
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMO Finance
- CRDL Health Care
- Exchange
- DMO Nasdaq
- CRDL Nasdaq
- Market Cap
- DMO N/A
- CRDL 134.5M
- IPO Year
- DMO N/A
- CRDL N/A
- Fundamental
- Price
- DMO $12.28
- CRDL $1.98
- Analyst Decision
- DMO
- CRDL Strong Buy
- Analyst Count
- DMO 0
- CRDL 3
- Target Price
- DMO N/A
- CRDL $9.00
- AVG Volume (30 Days)
- DMO 49.6K
- CRDL 330.5K
- Earning Date
- DMO 01-01-0001
- CRDL 11-19-2024
- Dividend Yield
- DMO 12.06%
- CRDL N/A
- EPS Growth
- DMO N/A
- CRDL N/A
- EPS
- DMO N/A
- CRDL N/A
- Revenue
- DMO N/A
- CRDL N/A
- Revenue This Year
- DMO N/A
- CRDL N/A
- Revenue Next Year
- DMO N/A
- CRDL N/A
- P/E Ratio
- DMO N/A
- CRDL N/A
- Revenue Growth
- DMO N/A
- CRDL N/A
- 52 Week Low
- DMO $10.00
- CRDL $0.72
- 52 Week High
- DMO $11.80
- CRDL $3.12
- Technical
- Relative Strength Index (RSI)
- DMO 62.69
- CRDL 53.36
- Support Level
- DMO $11.87
- CRDL $1.88
- Resistance Level
- DMO $12.18
- CRDL $2.24
- Average True Range (ATR)
- DMO 0.12
- CRDL 0.11
- MACD
- DMO 0.02
- CRDL 0.02
- Stochastic Oscillator
- DMO 98.78
- CRDL 46.94
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.